Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma
Mohammed A. Aljama(Juravinski Cancer Centre), Shaji Kumar(Mayo Clinic), David Dingli, Francis K. Buadi, Morie A. Gertz(Medical University of South Carolina), Nelson Leung(WinnMed), Dragan Jevremović(Mayo Clinic in Arizona), Robert A. Kyle(Mayo Clinic), Ronald S. Go(Mayo Clinic), Prashant Kapoor, Amie Fonder, Yi L. Hwa, Rahma Warsame, S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), Taxiarchis Kourelis(Mayo Clinic in Arizona), Arjun Lakshman(Mayo Clinic in Arizona), Martha Q. Lacy(Mayo Clinic), Eli Muchtar(Mayo Clinic), Suzanne R. Hayman, Angela Dispenzieri(Mayo Clinic), Miriam Hobbs, M Hasib Sidiqi(Curtin University)
Cited by 32
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k